Switch theme
Sign up to access all valuation multiples
Dishman Carbogen Amics Ltd is a biotechnology company that provides contract research and manufacturing services for pharmaceutical companies. It manufactures bulk drugs, specialty chemicals, and outsourced goods. Additionally, the company produces vitamins, such as vitamin D2 and vitamin D3, reagents, antiseptics and disinfectants, transfer catalysts, personal-care ingredients, pharma intermediates, and ammonium and phosphonium high-purity solid Quats. The business generates the vast majority of its revenue in India.
2007
1.1K+
Last FY Revenue $318M
Last FY EBITDA $55.3M
$704M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Dishman Carbogen Amics achieved revenue of $318M and an EBITDA of $55.3M.
Dishman Carbogen Amics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Dishman Carbogen Amics valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $318M | XXX | XXX | XXX |
| Gross Profit | XXX | $259M | XXX | XXX | XXX |
| Gross Margin | XXX | 81% | XXX | XXX | XXX |
| EBITDA | XXX | $55.3M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 17% | XXX | XXX | XXX |
| EBIT | XXX | $20.5M | XXX | XXX | XXX |
| EBIT Margin | XXX | 6% | XXX | XXX | XXX |
| Net Profit | XXX | $0.4M | XXX | XXX | XXX |
| Net Margin | XXX | 0% | XXX | XXX | XXX |
| Net Debt | XXX | $204M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Dishman Carbogen Amics's stock price is INR 266 (or $3).
Dishman Carbogen Amics has current market cap of INR 41.7B (or $488M), and EV of INR 60.1B (or $704M).
See Dishman Carbogen Amics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $704M | $488M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Dishman Carbogen Amics has market cap of $488M and EV of $704M.
Dishman Carbogen Amics's trades at 2.3x EV/Revenue multiple, and 14.0x EV/EBITDA.
Equity research analysts estimate Dishman Carbogen Amics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Dishman Carbogen Amics's P/E ratio is not available.
See valuation multiples for Dishman Carbogen Amics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $488M | XXX | $488M | XXX | XXX | XXX |
| EV (current) | $704M | XXX | $704M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 2.3x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 14.0x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 46.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -116.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 43.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDishman Carbogen Amics's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Dishman Carbogen Amics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Dishman Carbogen Amics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Dishman Carbogen Amics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 16% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 75% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Piramal Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Dishman Carbogen Amics acquired XXX companies to date.
Last acquisition by Dishman Carbogen Amics was XXXXXXXX, XXXXX XXXXX XXXXXX . Dishman Carbogen Amics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Dishman Carbogen Amics founded? | Dishman Carbogen Amics was founded in 2007. |
| Where is Dishman Carbogen Amics headquartered? | Dishman Carbogen Amics is headquartered in India. |
| How many employees does Dishman Carbogen Amics have? | As of today, Dishman Carbogen Amics has 1.1K+ employees. |
| Is Dishman Carbogen Amics publicy listed? | Yes, Dishman Carbogen Amics is a public company listed on BOM. |
| What is the stock symbol of Dishman Carbogen Amics? | Dishman Carbogen Amics trades under 540701 ticker. |
| When did Dishman Carbogen Amics go public? | Dishman Carbogen Amics went public in 2004. |
| Who are competitors of Dishman Carbogen Amics? | Similar companies to Dishman Carbogen Amics include e.g. Jubilant Pharmova, Biocon, Syngene International, Cohance Lifesciences. |
| What is the current market cap of Dishman Carbogen Amics? | Dishman Carbogen Amics's current market cap is $488M |
| Is Dishman Carbogen Amics profitable? | Yes, Dishman Carbogen Amics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
